IXINITY® breaks down barriers to affordable hemophilia B treatment.

IXINITY FREE Trial.

New IXINITY patients are eligible for 1 month of IXINITY free—up to 20,000 IU.

Consider switching patients to IXINITY and they can get their first month free.* After the first free month, patients covered by commercial insurance may continue to pay nothing out-of-pocket for IXINITY regardless of their income.

Use the FREE Trial Request Form to start your patients on IXINITY with a FREE trial.

The first shipment of IXINITY will come with Custom Ancillaries in a reusable pouch for convenient and easy organization of all infusion-related items.

*Up to 20,000 IU.

Your patients will receive an IXINITY Starter Kit with their FREE trial

Your patient's IXperience, on the go, no matter where their next adventure takes them. Includes an information-packed IXINITY brochure.

IXINITY Savings Program.

Patients with commercial or private insurance can receive up to $12,000 a year toward their out-of-pocket cost for IXINITY, with no income requirements and no additional monthly limits.

Patients are eligible if they have commercial health insurance. Other restrictions may apply, and a US prescriber and pharmacy are required.

  • This program does not cover costs if patients are on government healthcare coverage, such as Medicare, Medicaid, and TRICARE.
  • This program does not cover costs associated with administration of therapy, such as office visits, infusion costs, or other professional services.

Aptevo Therapeutics reserves the right to rescind, revoke, or amend this offer without notice.

Get your patients started by calling your IXperience Concierge™ at 1​-8​55​-IXI​NITY (1​-8​55-​49​4-​648​9).

*May depend on individual health insurance.

IXINITY Patient Assistance Program.

This program helps deliver treatment to those in need.

If your patients are uninsured or experience a lapse in their coverage, this program may provide treatment at reduced or no cost.

Find out if your patients are eligible by calling the IXperience Concierge at 1​-8​55​-IXI​NITY (1​-8​55​-4​94​-64​89).

Explore more about IXINITY

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Expand

INDICATIONS AND USAGE: IXINITY® [Coagulation Factor IX (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children ≥12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

CONTRAINDICATIONS: IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions, including anaphylaxis, may occur following IXINITY administration. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions.

Thromboembolism may occur when using IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis).

Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts.

The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information.

Medical Affairs e-mail: MedicalAffairs@apvo.com

To report an adverse event, please call 1-844-859-6675.

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Berwyn, PA: Aptevo BioTherapeutics LLC; August 2016.